The European Union’s comprehensive ban on mercury dental amalgam, effective January 1, 2025, marks a pivotal step toward eliminating a known neurotoxin from dentistry, aligning with the Minamata Convention on Mercury’s goal to “Make Mercury History”. In contrast, the United States, despite ratifying the treaty in 2013, permits the continued use of mercury dental amalgam, a material deceptively called “silver fillings” despite its approximately 50% mercury content. The U.S. Food and Drug Administration (FDA), a global leader in health policy, maintains a contradictory stance: acknowledging mercury’s risks for vulnerable populations while resisting mandatory patient disclosures and a phase-out. This regulatory failure, challenged by legal actions, peer-reviewed studies, and advocacy groups, undermines informed consent, exacerbates health inequities, and hinders global mercury reduction efforts. This mini-review examines the FDA’s policies, emphasizing its refusal to mandate disclosures, the health risks of mercury dental amalgam, and the necessity of safe removal protocols. Drawing on recent scientific evidence and international benchmarks, we argue for urgent reform to protect public health, the environment and align with global standards.